Rep. Carol D. Miller Sells Pfizer Inc. (NYSE:PFE) Shares

Posted by John Perry on Apr 16th, 2025

Representative Carol D. Miller (R-West Virginia) recently sold shares of Pfizer Inc. (NYSE:PFE). In a filing disclosed on April 11th, the Representative disclosed that they had sold between $1,001 and $15,000 in Pfizer stock on March 10th.

Representative Carol D. Miller also recently made the following trade(s):

Purchased $1,001 – $15,000 in shares of Aflac (NYSE:AFL) on 3/10/2025.
Purchased $1,001 – $15,000 in shares of Hershey (NYSE:HSY) on 3/10/2025.
Purchased $1,001 – $15,000 in shares of Gilead Sciences (NASDAQ:GILD) on 3/10/2025.
Purchased $1,001 – $15,000 in shares of Lockheed Martin (NYSE:LMT) on 3/10/2025.
Purchased $1,001 – $15,000 in shares of PepsiCo (NASDAQ:PEP) on 3/10/2025.
Purchased $1,001 – $15,000 in shares of Honeywell International (NASDAQ:HON) on 3/10/2025.
Sold $1,001 – $15,000 in shares of U.S. Bancorp (NYSE:USB) on 3/10/2025.
Purchased $1,001 – $15,000 in shares of CME Group (NASDAQ:CME) on 3/10/2025.
Sold $1,001 – $15,000 in shares of Target (NYSE:TGT) on 3/10/2025.
Purchased $1,001 – $15,000 in shares of American Water Works (NYSE:AWK) on 3/10/2025.

Pfizer Stock Performance

Pfizer stock opened at $22.45 on Wednesday. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The stock has a market cap of $127.30 billion, a PE ratio of 15.92, a P/E/G ratio of 0.64 and a beta of 0.67. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $31.54. The business’s 50-day moving average price is $25.09 and its two-hundred day moving average price is $26.31.

Pfizer (NYSE:PFE – Get Free Report) last issued its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, beating the consensus estimate of $0.48 by $0.15. The business had revenue of $17.76 billion during the quarter, compared to the consensus estimate of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The firm’s revenue was up 24.7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.10 EPS. As a group, analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Pfizer news, Director Ronald E. Blaylock bought 19,457 shares of the business’s stock in a transaction dated Thursday, February 13th. The shares were purchased at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the purchase, the director now directly owns 27,707 shares of the company’s stock, valued at approximately $710,684.55. This represents a 235.84 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 0.06% of the company’s stock.

Institutional Investors Weigh In On Pfizer

Hedge funds and other institutional investors have recently modified their holdings of the company. TD Private Client Wealth LLC boosted its stake in Pfizer by 2.7% during the 3rd quarter. TD Private Client Wealth LLC now owns 124,712 shares of the biopharmaceutical company’s stock valued at $3,609,000 after purchasing an additional 3,307 shares during the last quarter. Passumpsic Savings Bank lifted its holdings in shares of Pfizer by 8.4% in the third quarter. Passumpsic Savings Bank now owns 25,680 shares of the biopharmaceutical company’s stock valued at $743,000 after purchasing an additional 1,998 shares in the last quarter. Virtu Financial LLC bought a new stake in Pfizer during the third quarter worth $1,499,000. Westside Investment Management Inc. raised its position in Pfizer by 7.7% in the 3rd quarter. Westside Investment Management Inc. now owns 14,008 shares of the biopharmaceutical company’s stock valued at $404,000 after buying an additional 1,004 shares during the last quarter. Finally, Diamant Asset Management Inc. lifted its stake in Pfizer by 8.4% during the 3rd quarter. Diamant Asset Management Inc. now owns 8,515 shares of the biopharmaceutical company’s stock valued at $246,000 after acquiring an additional 660 shares in the last quarter. Institutional investors own 68.36% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have issued reports on PFE. Truist Financial lowered their target price on Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a report on Wednesday, December 18th. The Goldman Sachs Group reiterated a “neutral” rating and issued a $25.00 price objective (down previously from $32.00) on shares of Pfizer in a report on Tuesday, April 8th. Guggenheim reissued a “buy” rating on shares of Pfizer in a report on Tuesday, March 18th. Hsbc Global Res upgraded shares of Pfizer to a “strong-buy” rating in a report on Monday, March 10th. Finally, UBS Group decreased their price objective on Pfizer from $28.00 to $24.00 and set a “neutral” rating for the company in a report on Tuesday, April 8th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, six have assigned a buy rating and three have issued a strong buy rating to the stock. According to data from MarketBeat, Pfizer currently has a consensus rating of “Moderate Buy” and an average price target of $31.07.

View Our Latest Research Report on PFE

About Representative Miller

Carol Miller (Republican Party) is a member of the U.S. House, representing West Virginia’s 1st Congressional District. She assumed office on January 3, 2023. Her current term ends on January 3, 2027.

Miller (Republican Party) ran for re-election to the U.S. House to represent West Virginia’s 1st Congressional District. She won in the general election on November 5, 2024.

West Virginia’s 3rd Congressional District race was identified as a 2018 battleground that might have affected partisan control of the U.S. House in the 116th Congress. Incumbent Evan Jenkins (R) did not seek re-election in 2018, leaving the seat open. In the campaign, Miller emphasized her endorsement by President Donald Trump (R). Lara Trump, Senior Advisor to Donald J. Trump for President, Inc., said, “Carol is pro-coal, pro-Second Amendment, and pro-Trump through and through, and is prepared to tackle the opioid epidemic that’s affected countless West Virginians.” Miller also supported the construction of a wall on the southern U.S. border and the Tax Cuts and Jobs Act (TCJA).

Miller is a former Republican member of the West Virginia House of Delegates, representing District 16 from 2006 to 2018.

Miller has also worked in real estate and owns a bison farm.

Carol Miller was born in Columbus, Ohio. Miller graduated from Bexley High School in 1968. She earned a B.S. from Columbia College in 1972. Her career experience includes owning and operating Swann Ridge Bison Farm and working as a real estate manager.

Pfizer Company Profile

(Get Free Report)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.